Ralph Lazzara, MD
Amiodarone has been unique among antiarrhythmic agents introduced into the United States. Its clinical use has been almost entirely "compassionate use" as a last resort for life-threatening ventricular arrhythmias resistant to approved agents and often to other investigational agents. Placebo-controlled trials or simultaneous direct comparisons with standard agents did not take place before approval by the Food and Drug Administration (FDA) because they were not supported by the pharmaceutical industry. During this period of clinical use, amiodarone came to be considered to be so potent as to be in a class by itself in regard to therapeutic efficacy and in
Learn more about subscription options.
Register Now for a free account.
Lazzara R. Amiodarone and Torsade de Pointes. Ann Intern Med. 1989;111:549–551. doi: 10.7326/0003-4819-111-7-549
Download citation file:
Published: Ann Intern Med. 1989;111(7):549-551.
Cardiology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only